NCT06692270View on ClinicalTrials.gov

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

January 10, 2026

Study Completion Date

January 10, 2027

Conditions
Esophagus Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab 200mg Q3W, D1 ; 2 cycles

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06692270 - Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter